ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin ‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

ConclusionsSingle ‐agent nab‐paclitaxel was associated with promising outcomes and a tolerable safety profile as second‐line treatment for patients with advanced‐stage, nonsquamous non‐small cell lung cancer. There was no benefit from the addition of CC‐486 to nab‐paclitaxel.

Source: Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Daniel Morgensztern, Manuel Cobo, Santiago Ponce Aix, Pieter E. Postmus, Conrad R. Lewanski, Jaafar Bennouna, J ürgen R. Fischer, Oscar Juan‐Vidal, David J. Stewart, Gianpiero Fasola, Andrea Ardizzoni, Rafia Bhore, Marianne Wolfsteiner, De Tags: Original Article Source Type: research